Related coverage linked through entity extraction aliases.
Feb 16, 2026
Nicox SA received positive written feedback from a pre-NDA meeting with the FDA for NCX 470, a nitric oxide-donating bimatoprost eye drop for glaucoma. The NDA submission remains on track for summer 2026.
Feb 14, 2026
Ocular Therapeutix announced positive topline results from SOL-1, its Phase 3 superiority trial of AXPAXLI for wet age-related macular degeneration, meeting primary and durability endpoints with high statistical significance.
Feb 13, 2026
Recent studies demonstrate tirzepatide's efficacy extends beyond diabetes management, showing reduced glaucoma risk in diabetic patients and significant improvements in pediatric Type 2 diabetes treatment with superior weight loss outcomes.
